The Brigham and Women's Hospital, Inc.

Harvard College

Ionis Pharmaceuticals, Inc.

Howard Hughes Medical Institute

Isis Pharmaceuticals, Inc.

Massachusetts Institute of Technology

Astrazeneca Ab

University of California

Children's Medical Center Corporation

Richard Theodore Lee

Mark J Graham

Rosanne M Crooke

Loren Lee Looger

Eric R Schreiter

Jonathan S Marvin

Vincent Segers

James Pancoast

Kenneth W Dobie

Douglas A Melton

Amy J Wagers

Francesco Loffredo

Parth Patwari

Linda G Griffith

Tommaso Poggioli

Brett P Monia

Punit P Seth

Thazha P Prakash

Zheng Xin Dong

Robert F Poniatowski

Lee L Rubin

Ornella Barrandon

Huynh-Hoa Bui

Garth A Kinberger

Jeffrey R Crosby

Adam Mullick

Aldons J Lusis

Luis M Alvarez

William John Drury, Iii

Todd Vannelli

Eric Valeur

Maria Astrid Ölwegård-Halvarsson

Daniel Laurent Knerr

Eva Carina Ämmälä

Shalini Andersson

Aharon Helman

Jessica Garbern

Daniel Linden

Stefano Romeo

Sharon C Reimold

Scott D Solomon

Michael E Davis

Patrick Hsieh

Steven M Jay

Matthew Steinhauser

Brian Parks

Lida Katsimpardi

Brian Beach

James Cheng

Kimberly Paluch

The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.

GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof

Disclosed herein are a means to prevent and/or ameliorate age, disease and obesity associated metabolic diseases, such as diabetes and impaired glucose tolerance. Also disclosed are compositions and methods that relate to the findings that GDF11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis in aged mice administered a high fat diet. In particular, the methods and compositions described herein relate to increasing the level of GDF11 in a subject, thereby treating or preventing the development of obesity in the subject, reducing the metabolic consequences of obesity and improving the subject's metabolic health.

Method of treating or inhibiting glucose intolerance

Disclosed herein are methods for generating mature cardiomyocytes and compositions including mature cardiomyocytes. Also disclosed herein are methods for enhancing maturation of quiescent cardiomyocytes and compositions including mature quiescent cardiomyocytes.

Cardiomyocytes and compositions and methods for producing the same

The present disclosure provides methods of treating or preventing fatty liver disease and/or lowering cholesterol and LDL cholesterol levels in a subject. The present disclosure further provides methods of lowering expression of Pleckstrin and Sec7 Domain Containing 3 (PSD3) in a subject.

Method of treating fatty liver disease

Methods and compositions for rejuvenating skeletal muscle stem cells are disclosed.

Methods and compositions for rejuvenating skeletal muscle stem cells

Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.

Modulation of angiopoietin-like 3 expression

Treatment with GDF11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis

Provided herein are methods, compounds, and compositions for reducing expression of KEAP1 in animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate oxidative stress or a disease, disorder or condition related to oxidative stress an animal in need. Diseases, disorders or conditions related to oxidative stress include NASH, NAFLD, asthma and insulin resistance.

Methods of modulating KEAP1

This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.

IL1RL-1 as a cardiovascular disease marker and therapeutic target

The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.

Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage

Provided herein are methods, compounds, and compositions for reducing expression of an AGPAT5 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids, insulin resistance and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a cardiometabolic disease, disorder or condition, or a physiological marker thereof, in an individual in need.

Modulation of AGPAT5 expression

The present disclosure provides, inter alia, genetically encoded recombinant peptide biosensors comprising analyte-binding framework portions and signaling portions, wherein the signaling portions are present within the framework portions at sites or amino acid positions that undergo a conformational change upon interaction of the framework portion with an analyte.

Genetically encoded biosensors

The methods and uses described herein relate to the treatment of age-related conditions, e.g. by administering an agent that inhibits the interaction of GDF11 and follistatin. In some embodiments, the agent can bind to an epitope of GDF11 as described herein.

Growth differentiation factor (GDF) for treatment of diastolic heart failure

Growing community of inventors

Weston, MA, United States of America

Richard Theodore Lee